+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bone Marrow Transplant Rejection - Pipeline Review, H2 2020

  • ID: 5146895
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 797 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc
  • Boryung ViGenCell Inc
  • Educell doo
  • Immune Modulation Inc
  • Magenta Therapeutics Inc
  • REGiMMUNE Corp
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2020, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews the key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 11, 38, 17, 3, 44, 7 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Boryung ViGenCell Inc
  • Educell doo
  • Immune Modulation Inc
  • Magenta Therapeutics Inc
  • REGiMMUNE Corp

Introduction
  • Bone Marrow Transplant Rejection - Overview
  • Bone Marrow Transplant Rejection - Therapeutics Development

Bone Marrow Transplant Rejection - Therapeutics AssessmentBone Marrow Transplant Rejection - Companies Involved in Therapeutics DevelopmentBone Marrow Transplant Rejection - Drug Profiles
Bone Marrow Transplant Rejection - Dormant Projects
  • Bone Marrow Transplant Rejection - Discontinued Products
  • Bone Marrow Transplant Rejection - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Bone Marrow Transplant Rejection, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H2 2020
  • Bone Marrow Transplant Rejection - Pipeline by Adienne Pharma & Biotech, H2 2020
  • Bone Marrow Transplant Rejection - Pipeline by AltruBio Inc, H2 2020
  • Bone Marrow Transplant Rejection - Dormant Projects, H2 2020
  • Bone Marrow Transplant Rejection - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Bone Marrow Transplant Rejection, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc
  • Adienne Pharma & Biotech
  • AltruBio Inc
  • Amgen Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • ASC Therapeutics Inc
  • AstraZeneca Plc
  • Athersys Inc
  • Autolus Therapeutics Plc
  • Bellicum Pharmaceuticals Inc
  • Biocon Ltd
  • Biogen Inc
  • BioIncept LLC
  • BioTheryX Inc
  • BlueRock Therapeutics
  • Boryung ViGenCell Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cell Source Inc
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • Cellix Bio Pvt Ltd
  • CheckPoint Immunology Inc
  • Chipscreen Biosciences Ltd
  • Clinigen Group Plc
  • Compugen Ltd
  • CSL Ltd
  • CTI BioPharma Corp
  • Cytodyn Inc
  • Cytopeutics Pte Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dualogics Corp
  • Educell doo
  • Eli Lilly and Co
  • enGene Inc
  • Enlivex Therapeutics Ltd
  • Evive Biotech
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Fujifilm Holdings Corp
  • GigaGen Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glia LLC
  • Humanigen Inc
  • iCELL Biotechnology Co Ltd
  • Immplacate
  • Immune Modulation Inc
  • ImmuneTarget Inc
  • Imstem Biotechnology Inc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • ITB-Med AB
  • Jazz Pharmaceuticals Plc
  • JN Biosciences LLC
  • Kadmon Corp LLC
  • Kalytera Therapeutics Inc
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kiniksa Pharmaceuticals Ltd
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • Machavert Pharmaceuticals LLC
  • Magenta Therapeutics Inc
  • Mallinckrodt Plc
  • Medac Pharma Inc
  • Medicenna Therapeutics Corp
  • Mediolanum farmaceutici SpA
  • Medsenic SAS
  • Mereo Biopharma Group Plc
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • MitoImmune Therapeutics Inc
  • NapaJen Pharma Inc
  • Neovii Pharmaceuticals AG
  • Nurix Therapeutics Inc
  • OncoImmune Inc
  • OSE Immunotherapeutics
  • Panorama Research Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Platinum Biotech (Beijing) Co Ltd
  • Pluristem Therapeutics Inc
  • Precision Biosciences Inc
  • REGiMMUNE Corp
  • SCM lifescience Co Ltd
  • Seattle Genetics Inc
  • Secura Bio Inc
  • Seres Therapeutics Inc
  • STERO Biotechs Ltd
  • StingInn LLC
  • Suzhou Connect Biopharmaceuticals Ltd
  • Syndax Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TCF GmbH
  • TeraImmune Inc
  • TGV Laboratories Inc
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Visterra Inc
  • Xenikos BV
  • Xenothera SAS
  • XL-protein GmbH
Note: Product cover images may vary from those shown